|CBI -- Israel Stock|| |
ILS 288.20 3.40 1.17%
The recent Clal Biotechnology price drops could raise concerns from investors as the firm closed today at a share price of 287.5
in volume. The company management were unable to exploit market volatilities in February
. However, diversifying your overall positions with Clal Biotechnology Industries Ltd can protect your principal portfolio during market swings. The stock standard deviation of daily returns for 30 days (very short) investing horizon is currently 2.8154. The current volatility is consistent with the ongoing market swings in February 2019
as well as with Clal Biotechnology unsystematic, company specific events. This diagnostics interface makes it easy to digest most current publicly released information about Clal Biotechnology as well as get updates on important government artifacts including earning estimates, SEC corporate filings and announcements. This module also helps to analysis Clal Biotechnology price relationship with some important fundamental indicators such as market cap and management efficiency. Check also Trending Equities
Clal Biotechnology Note
The company recorded loss per share of 0.44. Clal Biotechnology had not issued any dividends in recent years. Clal Biotechnology Industries Ltd. is a private equity and venture capital firm specializing in development stage, pre-clinical incubation, seed, start-up, early venture, emerging growth, mid venture, late venture, PIPEs, and growth capital stages of financing. It operates as a subsidiary of Clal Industries and Investments Ltd. Clal Biotechnology operates under Biotechnology classification in Israel and is traded on Tel Aviv Stock Exchange. For more info on CLAL BIOTECH please contact the company at 972 3 612 1616 or go to http://www.cbi.co.il.
Clal Biotechnology Alerts
|Clal Biotechnology is not yet fully synchronised with the market data|
|Clal Biotechnology generates negative expected return over the last 30 days|
|The company reported revenue of 10.09M. Net Loss for the year was (67.78M) with profit before overhead, payroll, taxes, and interest of 11.03M. |
|CLAL BIOTECH has accumulated about 113.93M in cash with (98.26M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.64. |
The company currently falls under 'Small-Cap' category with current market capitalization of 435.44M.
Clal Biotechnology has return on total asset (ROA) of (5.85) %
which means that it has lost $5.85 on every $100 spent on asset. This is way below average. Similarly, it shows return on equity (ROE) of (10.34) %
meaning that it generated substantial loss on money invested by shareholders.
Stock Holders for Clal Biotechnology
Clal Biotechnology Technical and Predictive Indicators